Everything Breast Cancer
Hormones for High-Risk Patients: Getting it Straight, Keeping it Safe
Live Online • April 17–19, 2026
20 hours of CMEs for MDs, DOs, NDs, NPs, PAs, Nurses, and Pharmacists
Featuring
*Dr. Xan Simonson * Dr. Jenn Simmons * Dr. Thomas Seyfried * Dr. Daved Rosensweet * Carol Petersen, RPh, CNP * Dr. Paul Marik * Jim Hrncir, RPh * Jenn Goldstock, NP * Dr. Rebecca Glaser * Dr. Jeffrey Dach * Dr. Jessica Brownstein * Dr. Hailey Brownstein
* Dr. David Brownstein * Dr. Devaki Lindsey Berkson *
Everything Breast Cancer dives into one of the most complex and controversial areas in modern oncology: how to safely and effectively use hormones and integrative therapies in breast cancer patients and those at high risk.
During the 2.5 intensive days, you’ll learn to interpret breast cancer pathology and imaging, differentiate estrogen types and signaling pathways, evaluate when and how HRT can be considered in survivors, and integrate metabolic, mitochondrial, nutritional, and repurposed-drug strategies into care.
Multiple case-rich presentations by seasoned providers will help you connect the science to real-world protocols for high‑risk and breast cancer patients.
You have likely followed many of these experts through their lectures, articles, and books. Now, they come together in one comprehensive, clinically-focused CME intensive designed to help you get it straight and keep it safe.
Your registration includes lifetime access to all edited course recordings, plus a wealth of bonus materials, slide decks, protocols, and supplemental resources, so you can revisit the material and refine your protocols long after the live event ends.
CME Claim Deadlines:
Claim your CMEs within 30 days of the course to receive your certificate.
Questions?
Email [email protected]
Don’t miss this opportunity to elevate your breast cancer care, deepen your hormone expertise, and transform outcomes for your high‑risk patients.
CME Qualification Questions: Check with your Licensing Board
(Need International CME Credits? Often, there is mutual recognition of these CMEs with International CMEs. Check with your specific licensing board.)
CME Classification: AMA PRA Category 1 or CUE Credit Hours
CMEs for NDs: 7 hours General & 13 hours Pharmacology
Reserve your seat now to join the live sessions, ask your questions in real time, and keep lifetime access to all recordings and clinical resources.
Presenters – 14 Expert Clinicians & Researchers
*Dr. Xan Simonson * Dr. Jenn Simmons * Dr. Thomas Seyfried * Dr. Daved Rosensweet * Carol Petersen, RPh, CNP * Dr. Paul Marik * Jim Hrncir, RPh * Jenn Goldstock, NP *
Dr. Rebecca Glaser * Dr. Jeffrey Dach * Dr. Jessica Brownstein * Dr. Hailey Brownstein * Dr. David Brownstein * Dr. Devaki Lindsey Berkson *
Organizers & Presenters
Presenters
Early Bird Special Until February 28th
Use Code EBCEARLYBIRD at checkout for $100 off
Presentation Schedule
Day One
Session One – Why The Fear of Estrogen?
- Genomic vs non-genomic signaling
- Receptors and functions
- Estrogen seen as promoting “growth” vs “controlled” growth
- Review of HABITS study and 25 experimental studies
- BRCA genes & HRT
- Estrogen Timing Hypothesis debunked
Session Two – A Breast Surgeon’s Guidance on Diagnosis and Treatment
- Interpret pathology and imaging reports
- Breast cancer subtypes: adenocarcinoma, lobular, pure mucinous, DCIS, triple negative
- Biomarkers: Ki-67, VEGF
- Case reports
Session Three – Estrogen’s Real Science
- Human vs equine estrogen in proliferation rates & estrogen receptor targeting
- Criteria for HRT in breast cancer survivors
- Ki-67 markers and pathology parameters
- Three phases of Tamoxifen resistance
Session Four – Metabolic Cause and Treatment of Breast Cancer
- Major metabolic drivers of cancer & effective nutrients
- Adjunctive medications
- Nutrients to select/avoid during radiation and chemo
- Natural strategies for minimizing radiation & chemo effects
- How to protect healthy cells during chemotherapy
Session Five – Iodine: The Universal Anticancer Agent
- Therapeutic use of iodine in breast and other cancers
- Individualized dosing
- Testing and treatment duration
- Case reports
Session Six – 3 Experts – Case Reports: Using HRT in Breast Cancer Patients
- Histories, HRT protocols, and patient progress from three expert case reports
- Clinical implications of HRT in breast cancer patients
- Case-based insights to personalize HRT decisions for breast cancer survivors
Non-CME Q&A
Day Two
Session Seven – Testosterone and Breast Cancer
- Testosterone’s physiological role and intracrine conversion to estradiol
- The rationale and mechanism for T+AI in implants for breast cancer survivors
- Clinical benefits of T+AI therapy through the analysis of case reports
Session Eight – Natural ER Beta Agonists and Triple Negative Breast Cancer
- Natural aromatase inhibitors that modulate aromatase activity & genetic expression
- ERβ signaling roles and applications in triple-negative breast cancer
- ERβ signaling concepts through a clinical case
Session Nine – The Role of Repurposed Drugs in Treating Cancer
- The role of repurposed drugs for breast cancer and their tiered application
- Strategies to manage chemotherapy‑related adverse effects
- Nutrient safety during chemo/radiation and when to reintroduce supplementation
Session 10 – Cancer as a Mitochondrial Metabolic Disease
- Cancer as a mitochondrial metabolic disease
- Defective respiration/fermentation mechanisms regardless of heterogeneity
- Ketogenic Metabolic Therapy (KMT) as a therapeutic strategy for cancer management and its application through case reports
Session 11 – What Drives Recurrence: The Science, The Cases
- TGF‑β1 and dormant tumor cell roles in recurrence
- Botanicals and nutrients that inhibit dormant tumor cells
- Hydroxychloroquine + rapamycin phase 2 trial and mTOR pathway
Session 12 – Progesterone and Breast Cancer (and other cancers)
- Progesterone’s role in cancer development and treatment across organs.
- Progesterone’s aromatase and mTOR inhibitory effects
- Progesterone therapy concepts through multiple case analyses (including breast, endometrial, and ovarian cancers)
Session 13 – Food, Nutrients, Cancer T cell Upregulation, and More
- Bioactive food components that enhance T cell function
- Why anthocyanin-rich foods are essential for cancer patients
- The pros and cons of soy and strategies for patients with allergies
Session 14 – Case Studies: Breast Cancer Patients and Hormones
- Clinical histories and hormone protocols from multiple expert case reports
- Implications of hormone therapy in breast cancer
- Case insights for individualized hormone management
Non-CME Q&A
Day 3
Session 15 – Breast Cancer Pearls: From Dosing Melatonin to Treating Lymphedema
- Melatonin dosing
- Jordan’s estrogen‑deprivation theory
- Stair‑step hormone strategies and dietary recommendations
- Functional strategies for lymphedema, radiation burns, and kidney protection during chemotherapy
- Tracking spike protein IgG and how to “detoxify” this carcinogen
Session 16 – Hormone Testing and Efficacy
- Appropriate hormone testing for breast cancer patients
- Interpreting results for breast cancer patients
- Hormone bases and delivery modes comparisons (including special considerations)
- FSH monitoring to assess estrogen efficacy and tissue protection
Session 17 – Iodine and Breast Cancer Recurrence
- Iodine’s role in modulating estrogen metabolism for breast cancer prevention
- How DIM works with iodine to support estrogen pathways
- Iodine + DIM protocols for recurrence‑risk reduction.
Session 18 – What Nutrients Must Be Avoided During Allopathic Cancer Care and When to Restart?
- Nutrients to avoid during radiation/chemotherapy
- Appropriate timing to restart supplementation.
- Recommend protective nutrients for patients undergoing treatment
Session 19 – Hormones and High‑Risk Cardiac Patients
- Studies and delivery modes that support safe HRT use in high‑risk cardiac and genetic pro‑coagulatory patients.
- Estrogen’s cardioprotective mechanisms
- Strategies for cardiac protection during chemo
Session 20 – Iodine Controversies
- Common controversies around high‑dose iodine
- Safe clinical use of Iodine
- Testing for iodine deficiency
- Individualized replacement strategies.
- Functional approaches for thyroid and breast disorders
- Collaborative care with oncologists
